Results 101 to 110 of about 309,141 (294)

Applicability of mitotic figure counting by deep learning: a development and pan‐cancer validation study

FEBS Open Bio, EarlyView.
In this study, we developed a deep learning method for mitotic figure counting in H&E‐stained whole‐slide images and evaluated its prognostic impact in 13 external validation cohorts from seven different cancer types. Patients with more mitotic figures per mm2 had significantly worse patient outcome in all the studied cancer types except colorectal ...
Joakim Kalsnes, Maria X. Isaksen, Frida Julbø, Manohar Pradhan, Andreas Kleppe, Sepp De Raedt, Ole‐Johan Skrede, Turid Torheim, John Arne Nesheim, Hans Martin Mohn, Hanne A. Askautrud, Karolina Cyll, Wanja Kildal, Emma Rewcastle, Melinda Lillesand, Vebjørn Kvikstad, Emiel Janssen, Robert Jones, Odd Terje Brustugun, Bjørn Brennhovd, Erik Skaaheim Haug, Lill‐Tove Rasmussen Busund, Elin Richardsen, Sigve Andersen, Tom Dønnem, Kristina Lindemann, Gunnar Kristensen, Neil A. Shepherd, Marco Novelli, Knut Liestøl, David Kerr, Håvard E. Danielsen, Tarjei S. Hveem   +32 more
wiley   +1 more source

Circulating tumor cells isolation: The “post-EpCAM era” [PDF]

, 2015
Circulating tumor cells (CTCs) represent a submicroscopic fraction detached from a primary tumor and in transit to a secondary site. The prognostic significance of CTCs in metastatic cancer patients was demonstrated for the first time more than ten years
Gradilone, Angela, Nicolazzo, Chiara, Raimondi, Cristina   +2 more
core   +1 more source

Identifying gene expression signatures for risk stratification of postoperative adjuvant chemotherapy in colorectal cancer

FEBS Open Bio, EarlyView.
A novel signature integrating genome‐wide analysis with clinical factors predicts recurrence in stage II colorectal cancer and enables a new risk stratification to guide postoperative adjuvant chemotherapy. Clinical risk stratification for postoperative recurrence in patients with pathological stage II (pStage II) colorectal cancer (CRC) is essential ...
Mayuko Otomo, Keisuke Okuno, Shuichi Watanabe, Sakiko Oba, Hiroyasu Kagawa, Masanori Tokunaga, Daisuke Ban, Yusuke Kinugasa   +7 more
wiley   +1 more source

Early dissemination of bevacizumab for advanced colorectal cancer: a prospective cohort study

BMC Cancer, 2011
Background We describe early dissemination patterns for first-line bevacizumab given for metastatic colorectal cancer treatment. Methods We analyzed patient surveys and medical records for a population-based cohort with metastatic colorectal cancer ...
Fouad Mona N, Weeks Jane C, Zullig Leah L, Kolimaga Jane T, Schrag Deborah, Abbott David H, Grambow Steven C, Malin Jennifer L, Zafar S Yousuf, Ayanian John Z, Wallace Robert, Kahn Katherine L, Ganz Patricia A, Catalano Paul, West Dee W, Provenzale Dawn   +15 more
doaj   +1 more source

Shared Genetic Effects and Antagonistic Pleiotropy Between Multiple Sclerosis and Common Cancers

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Epidemiologic studies have reported inconsistent altered cancer risk in individuals with multiple sclerosis (MS). Factors such as immune dysregulation, comorbidities, and disease‐modifying therapies may contribute to this variability.
Asli Buyukkurt, Marius Ygonia, Ali Manouchehrinia, Philippe Lefrançois, Ingrid Kockum, Adil Harroud   +5 more
wiley   +1 more source

Retrospective analysis of KRAS status in metastatic colorectal cancer patients: a single-center feasibility study

Clinical and Experimental Gastroenterology, 2012
Jonathan Montomoli,1 Stephen Jacques Hamilton-Dutoit,2 Trine Frøslev,1 Aliki Taylor,3 Rune Erichsen11Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark; 2Institute of Pathology, Aarhus University Hospital, Aarhus,
Montomoli J, Hamilton-Dutoit SJ, Frøslev T, Taylor A, Erichsen R   +4 more
doaj  

Innovations in colorectal cancer treatment: trifluridine and tipiracil with bevacizumab for improved outcomes – a review

Frontiers in Oncology
Colorectal cancer ranks second in cancer-related deaths throughout the world. At the time of diagnosis, at least 20% of the patients with CRC had already developed metastases.
Taruba Rais, Rumaisa Riaz, Tasmiyah Siddiqui, Amna Shakeel, Afsheen Khan, Habiba Zafar   +5 more
doaj   +1 more source

The T-LAK Cell-originated Protein Kinase Signal Pathway Promotes Colorectal Cancer Metastasis

EBioMedicine, 2017
Approximately 90% of all cancer deaths arise from the metastatic dissemination of primary tumors. Metastasis is the most lethal attribute of colorectal cancer.
Tatyana A. Zykova, Feng Zhu, Lei Wang, Haitao Li, Ruihua Bai, Do Young Lim, Ke Yao, Ann M. Bode, Zigang Dong   +8 more
doaj   +1 more source

Unraveling the Molecular Mechanisms of Glioma Recurrence: A Study Integrating Single‐Cell and Spatial Transcriptomics

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Glioma recurrence severely impacts patient prognosis, with current treatments showing limited efficacy. Traditional methods struggle to analyze recurrence mechanisms due to challenges in assessing tumor heterogeneity, spatial dynamics, and gene networks.
Lei Qiu, Yinjiao Fei, Jiaxuan Ding, Kexin Shi, Jinyan Luo, Yuchen Zhu, Xingjian Sun, Gefei Jiang, Yuandong Cao, Weilin Xu, Shu Zhou   +10 more
wiley   +1 more source

Concomitant Primary Lung Cancer and Metastatic Pulmonary Colorectal Cancer that Responded to Gemcitabine/Cisplatin/Bevacizumab Combination Therapy

Journal of Cancer Research and Practice, 2015
The incidence of double primary malignancy in colorectal cancer is rare (approximately 1-6%), and synchronous double primary malignancy is even rarer for cases involving colorectal cancer. Indeed, its incidence is estimated to be less than 1%.
Hung-Ming Chen, Chin-Chen Pan, Chun-Ming Tsai, Wen-Hu Hsu, Shung-Haur Yang, Chueh-Chuan Yen   +5 more
doaj   +1 more source